Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Kalaris Therapeutics IncNASDAQ: KLRS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $374K a year earlier. Trailing-twelve-month stock-based compensation was $638K.

Context

  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $159.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$638K— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Stock-Based Compensation vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
KLRS Competitors
Stock-Based Compensation for KLRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$10.03M USD-58.5%-18.9%10.1%
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$6.36M USD-16.6%+1.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$3.73M USD-44.6%+54.6%5821.9%
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
OVIDOvid Therapeutics Inc.LTM Mar 2026$2.41M USD-6.9%-9.8%33.9%
CNTXContext Therapeutics Inc.LTM Mar 2026$1.45M USD+61.5%+10.9%—
IMAImageneBio IncLTM Mar 2026$1.39M USD-67.0%+26.9%—
KLRSKalaris Therapeutics IncLTM Mar 2026$638K USD———
Peer median (excluding KLRS) —-30.6%+2.7%768.9%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Depreciation & Amortization1.12M00013K
Deferred Income Tax00000
Stock-Based Compensation0271K148K00
Change in Working Capital19.35M3.4M(1.09M)(25.31M)3.43M
Accounts Receivables400K00206K0
Inventory00000
Accounts Payables20.29M1.83M(402K)(28.86M)(88K)
Other Working Capital(1.34M)1.57M(690K)3.35M3.52M
Other Non-Cash Items45.17M2.04M1.51M16.37M(2.98M)
Operating Cash Flow(106.32M)(9.78M)(14.13M)(67.71M)(42.98M)
Capital Expenditures(26K)000(200K)
Acquisitions (Net)00000
Purchases of Investments(76.59M)000(34.52M)
Sales of Investments262.6M0095M15M
Other Investing Activities00000
Investing Cash Flow185.98M0095M(19.72M)
Debt Repayment04.3M6M07.5M
Common Stock Issued232K0021K50M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities05K1.5M0102.11M
Financing Cash Flow232K12.78M14.24M21K159.61M
Effect of Forex Changes(896K)00852K(117.15M)
Net Change in Cash79M3M110K28.17M(20.24M)
Free Cash Flow(106.35M)(9.78M)(14.13M)(67.71M)(43.18M)

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.